Abstract
Olfactory impairment (decreased acuity, impaired adequate identification of odorants) reduces the quality of life of patients and can be a symptom of a wide range of pathologies of the organism, in particular neurodegenerative processes in the brain. Quantitative measurement of olfactory acuity is necessary for diagnostics of olfactory dysfunctions, monitoring the dynamics of olfaction after pharmacological or surgical treatment. The searching for optimal methods of analyzing olfactory thresholds on animal models of human diseases accompanied by anosmia and comparing them with those in humans seems to be especially urgent problem at the moment. This is necessary for the selection of a valid animal model for the evaluation of new drugs and development the therapy for a wide range of pathologies. The review analyzes publications devoted to the study of diseases accompanied by anosmia or hyposmia, their zootropic models, and methods of olfactory function assessment. Models for COVID19, Alzheimer’s disease, Parkinson’s disease, diabetes types (1 and 2 type), Kalman syndrome, and Bardet-Biedl syndrome, for which olfactory dysfunction and/or defects of olfactory system are present, were analyzed. The review notes the paucity of data on the measurement of olfactory thresholds in model animals.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have